Bcg Case Study

829 Words2 Pages

Orihuela and Smith [139] found a recurrence rate of 80% among patients who did not receive supplemental BCG versus a recurrence rate of 16.6% among those who did. However, an update of their series could not ultimately demonstrate a survival advantage with the addition of adjuvant BCG [111]. Rastinehad et al. [122] retrospectively studied 133 renal units treated by percutaneous resection for UTTCC. Eighty‐nine renal units treated primarily by percutaneous resection were then analyzed. Fifty renal units received adjuvant BCG therapy two weeks after endoscopic management for a total of six courses. Recurrence was defined as a positive biopsy result after the third‐look nephroscopy. Overall median follow‐up was 40.8 months. There was no statistical …show more content…

There was no statistical significance demonstrated between any of the treated and nontreated groups. The authors concluded that there is no overall oncologic benefit in the administration of adjuvant BCG with regard to disease recurrence, interval to recurrence, and progression of disease in the treatment of UTTCC. The latest analysis of this retrospective series from Smith’s group included 141 patients with median follow‐up of 66 months [143]. Nephroureterectomy was avoided in 87% of patients. Recurrence occurred in 37% of low‐grade UTTCC patients and 63% of high‐grade UTTCC patients, with a median time to recurrence of 71.4 versus 36.4 months, respectively. On multivariate analysis, grade was the only predictor of recurrence (HR 2.12, P = 0.018). Disease in one patient recurred after 116 months of surveillance, emphasizing the importance of long‐term follow‐up after endoscopic management of UTTCC. Similar to their previous analysis, BCG and mitomycin did not protect against recurrence, progression to nephroureterectomy, or death over resection alone

Open Document